Discovery through Partnership | Excellence through Quality
| Product Name | Rasagiline mesylate |
| Description |
MAO inhibitor |
| Purity | >99% (HPLC); NMR (Conforms) |
| CAS No. | 161735-79-1 |
| Molecular Formula | C12H13N • CH3SO3H |
| Molecular Weight | 267.3 |
| Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Properties
| Storage Temperature | -20ºC |
| Shipping Temperature | Shipped Ambient |
| Product Type | Inhibitor |
| Solubility | May be dissolved in DMSO (50 mg/ml); or water (50 mg/ml); Ethanol (30 mg/ml) |
| Source | Synthetic |
| Appearance | White crystalline powder |
| SMILES | C#CCN[C@@H]2CCC1=CC=CC=C12.CS(=O)(O)=O |
| InChI | InChI=1S/C12H13N.CH4O3S/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12;1-5(2,3)4/h1,3-6,12-13H,7-9H2;1H3,(H,2,3,4)/t12-;/m1./s1 |
| InChIKey | JDBJJCWRXSVHOQ-UTONKHPSSA-N |
| Safety Phrases |
GHS Classification: GHS07 Acute Toxicity (Category 4), Skin Irritant (Category 2), Eye Irritant (Category 2), Specific Target Organ Toxicity (Category 3) Hazard Statement: H302 Harmful if Swallowed |
| Cite This Product | Rasagiline mesylate (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-577) |
Biological Description
| Alternative Names | (1R)-2,3-Dihydro-N-2-propynyl-1H-inden-1-amine, methanesulfonate; TVP-1012; Azilect |
| Research Areas | Neurodegeneration, Neuroscience, Parkinson's Disease, Synuclein |
| PubChem ID | 3052775 |
| Scientific Background | MAO-B inhibitor used in Parkinson’s disease. Enhances dopaminergic signaling, prevents α-synuclein toxicity, restores TrkB signaling, and increases BDNF levels. |
| References |
1. Stocchi F., Fossati C1, Torti M. (2015) Expert Opin Pharamcorther. 16(14): 2231-2241. 2. Chau KY., Cooper JM., Schapire AHV. (2010) Neurochem Int. 57(5): 525-529. |
Product Images
Chemical structure of Rasagiline mesylate (SIH-577), a MAO Inhibitor. CAS #: 161735-79-1. Molecular Formula: C12H13N • CH3SO3H. Molecular Weight: 267.3 g/mol.
Powered by Bioz
Reviews
There are no reviews yet.